HC Wainwright Comments on Evommune FY2025 Earnings

Evommune, Inc. (NYSE:EVMN) – Analysts at HC Wainwright issued their FY2025 earnings per share (EPS) estimates for shares of Evommune in a research report issued on Tuesday, January 6th. HC Wainwright analyst M. Kapoor anticipates that the company will post earnings per share of ($4.36) for the year. HC Wainwright currently has a “Buy” rating and a $35.00 target price on the stock. HC Wainwright also issued estimates for Evommune’s Q4 2025 earnings at ($0.42) EPS, Q1 2026 earnings at ($0.36) EPS, Q2 2026 earnings at ($0.34) EPS, Q3 2026 earnings at ($0.35) EPS, Q4 2026 earnings at ($0.36) EPS and FY2026 earnings at ($1.40) EPS.

A number of other brokerages have also weighed in on EVMN. The Goldman Sachs Group raised shares of Evommune to a “buy” rating in a research note on Wednesday. Leerink Partnrs upgraded shares of Evommune to a “strong-buy” rating in a report on Monday, December 1st. Raymond James Financial began coverage on Evommune in a report on Wednesday. They set a “strong-buy” rating on the stock. William Blair began coverage on Evommune in a research report on Monday, December 1st. They issued an “outperform” rating for the company. Finally, Evercore ISI began coverage on Evommune in a research report on Monday, December 1st. They set an “outperform” rating and a $40.00 price target on the stock. Two investment analysts have rated the stock with a Strong Buy rating, seven have issued a Buy rating and one has assigned a Hold rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Buy” and an average target price of $38.60.

Evommune Stock Up 0.9%

Shares of Evommune stock opened at $16.22 on Thursday. Evommune has a 12-month low of $13.89 and a 12-month high of $24.03.

Evommune (NYSE:EVMN) last announced its earnings results on Thursday, December 11th. The company reported ($8.07) EPS for the quarter, missing analysts’ consensus estimates of ($6.58) by ($1.49). The company had revenue of $10.00 million during the quarter, compared to the consensus estimate of $10.00 million.

Evommune Company Profile

Evommune is a clinical-stage biotechnology company developing innovative therapies that target key drivers of chronic inflammatory diseases, with initial clinical development programs focusing on chronic spontaneous urticaria (“CSU”), atopic dermatitis (“AD”) and ulcerative colitis (“UC”). Chronic inflammation is a significant healthcare problem in the world, substantially impacting patients’ quality of life and leading to life-threatening conditions. These conditions, if not prevented, ultimately lead to fatal diseases, such as cardiovascular diseases, diabetes and cancer, which contribute to three out of every five deaths worldwide and result in an estimated $90 billion of annual cost to the healthcare system in the United States.